Cell News and Research

RSS

Moderate alcohol consumption may reduce risk of kidney cancer

A majority of previous epidemiologic studies have shown that moderate drinking is associated with a lower risk of kidney cancer, which may affect about 1% of the general population. In published prospective cohort studies, the risk for such cancer among moderate drinkers is usually about 25% less than the risk seen among non-drinkers.

20 Jul 2012

SGC, Life Technologies to generate first-ever master set of epigenetic recombinant antibodies

Life Technologies Corporation today announced it has signed a collaborative partnership with the Structural Genomics Consortium (SGC), and several groups of leading expert scientists in antibody technology at the Universities of Chicago and Toronto, to generate a first-ever master set of quality epigenetic recombinant antibodies for use in disease-related research.

20 Jul 2012

Studies report on therapeutic efficacy of stem cell transplantation in animal models of ALS, SCI

Two studies published in a recent issue of Cell Medicine report on the therapeutic efficacy of stem cell transplantation in animal models of amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI).

20 Jul 2012

New blood sugar monitor: An interview with Sherita Hill Golden

Type 1 diabetes is a disorder in which the body makes proteins (antibodies) against the cells in the pancreas that produce insulin, destroying those cells. As a result, individuals are unable to secrete insulin to normalize blood sugar and hyperglycemia results.

20 Jul 2012

Researchers identify six genes with driving mutations in melanoma

It's been a burning question in melanoma research: Tumor cells are full of ultraviolet (UV)-induced genetic damage caused by sunlight exposure, but which mutations drive this cancer? None have been conclusively tied to melanoma. The sheer abundance of these passenger mutations has obscured the search for genetic driver mutations that actually matter in melanoma development and progression.

20 Jul 2012

Internal clock of human skin responsible for time-based steering of repair and regeneration

A research team at Charité - Universitätsmedizin Berlin together with scientists at a company in Hamburg has now discovered that human skin has an internal clock responsible for the time-based steering of its repair and regeneration, among other things. The team published its first results from their basic research in the current issue of Proceedings of the Academy of Science (PNAS).

20 Jul 2012

Study helps explain why leukemia occurs more frequently as people age

Hundreds of mutations exist in leukemia cells at the time of diagnosis, but nearly all occur randomly as a part of normal aging and are not related to cancer, new research shows.

20 Jul 2012

Conatus, University of Alberta initiate islet cell transplant Phase I/II trial of emricasan for diabetes

Conatus Pharmaceuticals Inc. and the University of Alberta announced today the treatment of the first patient in an investigator-initiated islet cell transplant Phase I/II trial of emricasan (IDN-6556), a pan-caspase inhibitor.

20 Jul 2012

Actinium completes Actimab-A Phase I/II study on Acute Myeloid Leukemia

Actinium Pharmaceuticals, Inc. a biotechnology company focused on developing innovative, alpha particle radiotherapy targeted cancer treatments addressing major unmet medical needs, today announced that it has successfully treated the first cohort of patients in a Phase I/II study of Actimab-A in Acute Myeloid Leukemia (AML) clinical trial. Patients were treated at Memorial Sloan Kettering Cancer Center in New York City.

20 Jul 2012

BrainStorm completes registered public offering of common stock

BrainStorm Cell Therapeutics Inc., an innovative developer of adult stem cell technologies and Central Nervous System (CNS) therapeutics, today announced that it completed a registered public offering of 19,818,972 shares of common stock at a price per share of $0.29 and warrants to purchase 14,864,229 shares of common stock at an exercise price of $0.29 per share, representing gross proceeds of $5,747,502.

20 Jul 2012

BioDiem signs agreement with RMIT to create new non-influenza vaccines

Australian infectious disease therapy and vaccine development company BioDiem Ltd (ASX: BDM) today announced that BioDiem has signed an agreement with The Royal Melbourne Institute of Technology (RMIT) regarding a research program that will investigate the use of BioDiem’s live attenuated influenza virus (LAIV) to create new non-influenza vaccines. Developing the potential of the LAIV technology for new indications is an important part of BioDiem’s strategy, and this research is part of the work towards that goal.

19 Jul 2012

Robotic surgery shows promise for local control of OSCC

In individuals with low-risk oropharyngeal squamous cell carcinoma, treatment with transoral robotic surgery alone can result in an excellent rate of local disease control for up to 3 years, report researchers.

19 Jul 2012

Researchers discover potential drug targets that might reduce ventilator-induced lung inflammation

When hospital patients need assistance breathing and are placed on a mechanical ventilator for days at a time, their lungs react to the pressure generated by the ventilator with an out-of-control immune response that can lead to excessive inflammation, new research suggests.

19 Jul 2012

UNMC's ART injectables can successfully treat HIV infection

This has been a good week for breakthroughs in HIV/AIDS. Earlier this week, the Food and Drug Administration approved a daily pill, Truvada, which reduces the risk of HIV infection. Today, a University of Nebraska Medical Center research team's progress toward developing weekly or twice-monthly injectable antiretroviral therapy (ART) nanomedicines for patients with human immunodeficiency virus (HIV) infection will be highlighted as the cover story in the Journal of Infectious Diseases.

19 Jul 2012

Bryologs more potent than prostratin in treating HIV

Thanks to antiretrovirals, an AIDS diagnosis hasn't been a death sentence for nearly two decades. But highly active antiretroviral therapy, or HAART, is also not a cure.

19 Jul 2012

Elsevier introduces Respiratory Medicine Case Reports journal

Elsevier, a world-leading provider of scientific, technical and medical information products and solutions, is pleased to announce the launch of Respiratory Medicine Case Reports, a new online open access journal on general respiratory medicine that is dedicated to publishing case reports.

19 Jul 2012

Statistical method uses evolutionary information to enhance identification of disease-associated alleles

A book containing misprints may cause annoyance for the reader, but typos in an individual's genetic blueprint (DNA) can mean serious disease or even death. The search for genetic correlates for the wide range of diseases plaguing humankind has inspired a wealth of research falling under the heading of genome-wide association studies (GWAS).

19 Jul 2012

Duke-led consortium to focus on inducing neutralizing antibodies for HIV-1 prevention

Two Los Alamos National Laboratory scientists are among the team recently funded to explore ways to create the precise immune factors needed for effective vaccines against HIV.

19 Jul 2012

New research sheds light on pluripotency

New research at the Hebrew University of Jerusalem sheds light on pluripotency-the ability of embryonic stem cells to renew themselves indefinitely and to differentiate into all types of mature cells.

19 Jul 2012

Researchers verify role of alpha-synuclein aggregates in vivo

Using a two-photon microscope capable of peering deep within living tissue, researchers at the University of California, San Diego School of Medicine have found new evidence that alpha-synuclein protein build-up inside neurons causes them to not only become "leaky," but also to misfire due to calcium fluxes.

19 Jul 2012